Oxyimino compounds and the use thereof
    21.
    发明授权
    Oxyimino compounds and the use thereof 有权
    氧亚氨基化合物及其用途

    公开(公告)号:US08563732B2

    公开(公告)日:2013-10-22

    申请号:US12602441

    申请日:2008-05-30

    IPC分类号: A61K31/44 C07D211/00

    CPC分类号: C07D211/96

    摘要: The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

    摘要翻译: 本发明涉及(式I)的氧亚氨基化合物及其药学上可接受的盐,前药和溶剂化物,其中:Y是CO或SOm; Z是氢,每个任选取代的低级烷基,低级烯基,芳基,杂环基等.R 1和R 2各自独立地为氢,各自为任意取代的低级烷基,低级烯基,环烷基,芳基,杂环基等,各X独立地为= 任选取代的低级烷基,氰基,硝基等,m为1或2,p为O,1或2,q为O或1.本发明还涉及式I的用途化合物,以治疗,预防或改善 对钙通道阻断,特别是N型钙通道的阻滞作用。 本发明的化合物特别适用于治疗疼痛。

    FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE
    22.
    发明申请
    FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE 有权
    融合的氨基二氢吡啶衍生物

    公开(公告)号:US20130210839A1

    公开(公告)日:2013-08-15

    申请号:US13881112

    申请日:2011-10-27

    IPC分类号: C07D487/04

    CPC分类号: C07D487/04 A61K31/519

    摘要: The present invention provides, for example, the following compound: wherein ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, X1—X2═X3 is CR5—CR6═CR7, N—CR6═CR7, CR5—N═CR7 or CR5—CR6═N, R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R4a, R4b, R5, R6 and R7 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, its pharmaceutically acceptable salt or a solvate thereof having an effect of inhibiting amyloid β production, especially a BACE1 inhibitory activity, and useful as a medicament for treating diseases induced by production, secretion or deposition of amyloid β proteins.

    摘要翻译: 本发明例如提供以下化合物:其中环A为取代或未取代的碳环或取代或未取代的杂环,X1-X2 = X3为CR5-CR6 = CR7,N-CR6 = CR7,CR5-N = CR7或CR5-CR6 = N,R1是取代或未取代的烷基,取代或未取代的烯基等,R2a和R2b各自独立地为氢,取代或未取代的烷基等,R4a,R4b,R5,R6和R7各自为 独立地是氢,卤素,羟基,取代或未取代的烷基等,其药学上可接受的盐或其溶剂合物具有抑制淀粉样蛋白β产生的作用,特别是BACE1抑制活性,并且可用作治疗由生产诱导的疾病, 淀粉样β蛋白的分泌或沉积。

    Nitrogen-containing heterocycle derivatives substituted with cyclic group
    23.
    发明授权
    Nitrogen-containing heterocycle derivatives substituted with cyclic group 失效
    用环状基团取代的含氮杂环衍生物

    公开(公告)号:US07935706B2

    公开(公告)日:2011-05-03

    申请号:US12278412

    申请日:2007-02-21

    IPC分类号: A61K31/497

    摘要: It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR3R4)m-, —CO(CR3R4)n-, —CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

    摘要翻译: 发现由式(I)表示的含氮杂环衍生物特异性结合NR1 / NR2B的受体,并用作NR2B受体拮抗剂。 由下式表示的化合物:其中Z为N或CR1,A1为任选取代的含氮芳族单环基团,任选取代的含氮芳族稠合环基等,A2为芳族烃环基或 芳族杂环基,各自任选具有取代基,R 1,R 2,R a,R b,R c和R d各自独立地为氢,羟基等,w为2或3,t为1或2,X为 - (CR 3 R 4)m - ,-CO(CR 3 R 4)n - , - CONR 5(CR 3 R 4)n - 等,m为1〜4的整数,n为0〜4的整数,R 3和R 4各自独立地为氢,卤素,羟基等 R5为氢或低级烷基,或其药学上可接受的盐或溶剂合物。

    Oxazine derivatives
    26.
    发明授权
    Oxazine derivatives 有权
    恶嗪衍生物

    公开(公告)号:US08999980B2

    公开(公告)日:2015-04-07

    申请号:US13513839

    申请日:2010-12-10

    摘要: The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins.A compound of the formula (I): wherein R1, R2a, R2b, R3, R4a, R4b, ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

    摘要翻译: 本发明例如提供下述化合物作为治疗或预防由淀粉样蛋白的生产,分泌或沉积引起的疾病的药物。 蛋白质。 式(I)的化合物:其中R1,R2a,R2b,R3,R4a,R4b,环A和虚线在本说明书中定义,其药学上可接受的盐或溶剂合物。

    OXAZINE DERIVATIVES
    28.
    发明申请
    OXAZINE DERIVATIVES 有权
    氧气衍生物

    公开(公告)号:US20120245157A1

    公开(公告)日:2012-09-27

    申请号:US13513839

    申请日:2010-12-10

    摘要: The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins.A compound of the formula (I): wherein R1, R2a, R2b, R3, R4a, R4b, ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

    摘要翻译: 本发明例如提供下述化合物作为治疗或预防由淀粉样蛋白的生产,分泌或沉积引起的疾病的药物。 蛋白质。 式(I)的化合物:其中R1,R2a,R2b,R3,R4a,R4b,环A和虚线在本说明书中定义,其药学上可接受的盐或溶剂合物。